

AstraZeneca 

FluMist: Meeting the Challenges of the '20-'21 Flu Season

Alan Green
US Commercial Lead, FluMist

Flu Summit, 2020



1

AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

Our US FluMist Vision

To be an essential part of your Flu Vaccination Program, trusted by Healthcare Providers, Parents and Patients





2



3

Scientific and Operational advances are delivering results

SCIENTIFIC ADVANCES

- Strain filtration advances
- Proprietary genetic enhancement techniques
- Increased strains evaluated prior to WHO selection

SUPPLY CONFIDENCE

- WHO Collaboration
- End to End Supply Chain Improvements
- Monovalent production rate increased

PROCESS IMPROVEMENTS

4

Scientific and Operational advances are delivering results

2020-'21 Season

19M doses globally

8.75M doses in the US

5

What are your expectations of a manufacturing partner?



6